Darling Ingredients Inc. (DAR) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. While there are positive elements such as strong financial metrics, potential growth in the Feed Segment, and a promising joint venture, concerns arise from regulatory uncertainties, unclear guidance, and the hesitancy to provide precise forecasts. The Q&A section highlights these uncertainties, particularly around margins and regulatory impacts. The lack of clarity from management on critical issues tempers the positive aspects, leading to a neutral sentiment. Without a clear market cap, the stock price is expected to remain stable in the short term.
Key Financial Performance
Combined Adjusted EBITDA $245 million for Q3 2025, up from $237 million in Q3 2024, representing a year-over-year increase. The increase was driven by strong performance in the Global Ingredients business, which contributed $248 million of EBITDA.
Global Ingredients Business EBITDA $248 million for Q3 2025, up from $198 million in Q3 2024. The increase was attributed to robust global demand and exceptional execution across operations.
Renewables Business EBITDA (DGD) Negative $3 million for Q3 2025, down from positive $39 million in Q3 2024. The decline was due to a $38 million lower of cost or market (LCM) expense, higher feedstock costs, lower RINs and LCFS pricing, and a scheduled turnaround of DGD3.
Feed Segment EBITDA $174 million for Q3 2025, up from $132 million in Q3 2024. The increase was driven by strong demand for fats and proteins, solid execution, and improved gross margins.
Feed Segment Total Sales $1 billion for Q3 2025, up from $928 million in Q3 2024. The increase was supported by robust demand for domestic fats and improved global rendering volumes.
Food Segment Total Sales $381 million for Q3 2025, up from $357 million in Q3 2024. The increase was attributed to strong raw material sourcing and disciplined margin management.
Food Segment EBITDA $72 million for Q3 2025, up from $57 million in Q3 2024. The increase was due to higher sales and improved gross margins.
Fuel Segment Combined Adjusted EBITDA $22 million for Q3 2025, down from $60 million in Q3 2024. The decline was primarily due to lower earnings at DGD and challenges in the renewable fuels market.
Total Net Sales $1.6 billion for Q3 2025, up from $1.4 billion in Q3 2024. The increase was driven by steady raw material volumes and improved gross margins.
Gross Margins 24.7% for Q3 2025, up from 22.1% in Q3 2024. The improvement was due to strong performance across segments.
Raw Material Volumes 3.8 million metric tons for Q3 2025, steady compared to Q3 2024. The stability supported consistent sales performance.
Net Income $19.4 million for Q3 2025, up from $16.9 million in Q3 2024. The increase was due to improved performance in core business segments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Nextida Glucose Control product: Repeat orders continue, and early studies on new formulations look promising. A new Nextida product is on track for launch in the back half of 2026.
Global rendering business: Demonstrated stronger year-over-year performance, particularly in Brazil, Canada, and Europe. Export protein demand is recovering with firmer pricing trends.
U.S. domestic fats demand: Boosted by strong national agriculture and energy policy, leading to increased revenue and margins.
Core Ingredients Business: Delivered its strongest performance in 1.5 years, driven by robust global demand and exceptional execution. Combined adjusted EBITDA for Q3 was $245 million.
Feed Segment: EBITDA improved to $174 million from $132 million a year ago, with total sales of $1 billion versus $928 million last year. Gross margins improved to 24.3% from 21.5%.
Food Segment: Total sales were $381 million, up from $357 million in Q3 2024. Gross margins increased to 27.5% from 23.9%, and EBITDA rose to $72 million from $57 million.
Renewables Market: Facing short-term challenges due to higher feedstock costs, lower RINs and LCFS pricing, and policy delays. However, the company anticipates a shift with thoughtful public policy aimed at strengthening American agriculture and energy leadership.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Renewables Market Uncertainty: The renewables market is facing short-term uncertainty due to delays in finalizing the renewable volume obligation (RVO) ruling, negatively impacting the biofuel environment in the U.S.
Negative EBITDA in DGD: Diamond Green Diesel (DGD) posted a negative $3 million EBITDA, driven by higher feedstock costs, lower RINs and LCFS pricing, and a scheduled turnaround at DGD3, which reduced renewable diesel and sustainable aviation fuel volumes.
Tariff Implications: Tariffs, particularly in China and APAC countries, have impacted the value-added poultry protein products, affecting global pet food and aquaculture customers.
Biofuel Market Challenges: The biofuel market in the U.S. is challenged by policy delays, including RVO enforcement dates, small refinery exemptions (SREs), and clarity on reallocations, leading to an oversupply of RINs and lower biofuel margins.
Animal Disease Impact: Lower fuel segment volumes were affected by animal disease in Europe, reducing production by 351,000 metric tons compared to 391,000 metric tons in 2024.
Debt Levels: Total debt net of cash increased to $4.01 billion, with contributions to DGD and earn-out payments related to acquisitions adding to financial pressures.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Renewables Market Outlook: The renewables market is facing short-term uncertainty due to delays in the renewable volume obligation (RVO) ruling. However, the company anticipates a shift in public policy that will strengthen American agriculture and energy leadership, potentially enhancing Diamond Green Diesel's (DGD) earnings.
Nextida Product Launch: The company is on track to launch its new Nextida product in the second half of 2026, with promising early studies on new formulations.
Biofuel Market Projections: The EPA's supplemental proposal on RVO enforcement could lead to higher prices for feedstocks, farm products, and wider margins for biofuels in 2026 and 2027.
Production Tax Credits (PTCs): The company expects to generate $300 million in PTCs for 2025, with $200 million anticipated to be monetized by year-end and the remainder in early 2026.
Core Ingredients Business Guidance: For the full year 2025, the company expects EBITDA for the core ingredients business, excluding DGD, to range between $875 million and $900 million.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the most likely timeline for clarity on outstanding regulatory items like RVO, exemptions, and reallocation?
A:The government shutdown has made it difficult to predict, but the EPA considers the RVO an essential process. Optimistically, the comment period may close in December, and the EPA might submit their proposal to the Office of Management and Budget for approval by the end of the year.
Q:Does the price of waste fats and oils need to rebound for 4Q to look similar to 3Q?
A:The midpoint of the core ingredients EBITDA guidance implies 4Q will be comparable to 3Q. Waste fat prices have dipped, but prices remain strong in Brazil and Canada. The business is expected to come close to the guidance range of $875 million to $900 million.
Q:What are the benefits of RINs policy protectionism on the feed side?
A:The EPA's treatment of foreign feedstocks is unclear. North America has sufficient crop oils for biofuels, but foreign feedstocks may be required to meet mandates. The impact of penalties or tariffs on foreign feedstocks is uncertain, but domestic feedstocks may price at a premium.
Q:What drove the better-than-expected 3Q DGD margins?
A:The better capture rate reported by Valero was due to their accounting treatment of LCM against other segments, not the renewables or DGD segment. This made the capture rate appear better.
Q:What is the outlook for 4Q DGD margins?
A:Indicator margins are stronger, and the two big units in Port Arthur and Norco are operating at capacity. However, RIN values have not yet reflected the restarting of the industry. Margins have improved so far in the quarter, but clarity on the final RVO for '26 and '27 is needed for certainty.
Q:What factors contributed to the improvement in Feed segment margins?
A:Feedstock prices have increased, and protein prices have improved globally. Tariffs and trade dynamics with China and Vietnam have influenced the market. Strong prices are expected to carry into 4Q, with momentum likely continuing into next year.
Q:Could the RIN balance improve if facilities dependent on imported feedstocks shut down?
A:Yes, the RIN balance could become more constructive if facilities dependent on imported feedstocks shut down. Losses at these plants are substantial, and the proposed RVO for '26 and '27 is larger, suggesting margins need to improve to meet mandates.
Q:What RIN pricing is needed for the industry to meet the 2026 mandate?
A:Assuming no PTC and half a RIN for foreign feedstocks, RINs likely need to increase by $0.40 to incentivize enough production to meet the 2026 mandate.
Q:What are the plans for paying off debt and leverage restrictions?
A:The company is committed to paying down debt, with a debt coverage ratio expected to be around 3x by year-end. Long-term, the goal is to reduce leverage to 2.5x. There is significant headroom in the revolver, and no covenants are near being breached.
Q:What regulatory uncertainties remain around the RVO?
A:Uncertainties include the treatment of foreign biofuels, domestic feedstocks, and carbon intensity penalties. The EPA has proposed a 50% RIN for foreign biofuels with no PTC access, but clarity is needed on enforcement and tariffs.
Q:How is the PTC monetization process progressing?
A:The process has improved as counterparties become more familiar with the credit and tax liabilities become clearer. The company is confident in selling the majority of credits generated in 2025, with a more consistent process expected through 2026.
Q:What is the outlook for DGD in 4Q and 2026?
A:DGD margins have improved, and the outlook for 2026 is optimistic. However, the company is hesitant to provide precise guidance due to policy uncertainties. The restart of DGD1 depends on soybean oil profitability and a sustained margin outlook.
Q:What is the outlook for the Food segment?
A:The Food segment faced delays in orders due to tariff uncertainties but is expected to be stronger in 4Q. Hydrolyzed collagen business is rebounding, and new products like Nextida Brain are expected to contribute positively.
Q:What is the expected timeline for California LCFS credit value improvement?
A:The LCFS credit value is expected to improve steadily starting in 2026 as the supply-demand balance comes into alignment. The delay in implementing greenhouse gas reduction obligations has contributed to the current weak levels.
Q:Are there minimum pricing levels in place for the protein business in the U.S.?
A:Some contracts include minimum processing fees and participation in price value above certain thresholds. However, the focus is more on fat prices due to their higher volatility and upside potential.
Q:What is the impact of European tariffs on SAF production and sales?
A:The tariffs on U.S. SAF imports will affect new contracts but not current production, as most SAF for 2026 is already sold. The company remains optimistic about voluntary markets in the U.S. and the overall SAF outlook.
Q:What drove the improvement in the Fuel Ingredients business excluding DGD?
A:The improvement was driven by the green gas business and mortality destruction operations in Europe. Energy prices remain strong, and input costs have fluctuated, contributing to better gross margins.
Q:Why has the core EBITDA guidance been updated to $875 million to $900 million?
A:The updated guidance reflects the amalgamation of all three segments, excluding DGD. The business faces challenges in providing precise guidance due to price and volume volatility.
Q:What is the feedstock mix at DGD, and has it shifted recently?
A:DGD's feedstock mix has not materially shifted and remains focused on UCO, yellow grease, and animal fats. The company has redomesticated its supply chain to rely more on Darling's feedstocks, improving visibility in core ingredients business earnings.
Q:What is needed to restart DGD1?
A:DGD1 will only restart when soybean oil profitability and margin outlook justify the cost of burning up a catalyst. The current environment looks more favorable than a few months ago.
Q:Review of Unclear Management Responses
A:Management avoided giving direct answers or lacked clarity on several questions, including:
1. The exact treatment of foreign feedstocks by the EPA and the potential penalties or tariffs.
2. Specific details on the timeline and impact of regulatory uncertainties around the RVO and reallocation.
3. Precise guidance on DGD margins and the restart of DGD1 due to policy uncertainties.
4. The exact impact of European SAF tariffs on future contracts and production.
5. The timeline for significant improvement in California LCFS credit values.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Chief
DGD volume
Darling Ingredients
EPA proposal
Europe
Feed
Food segment
Global
LCM loss
LIFO LCM
PTCs
RVO ruling
SRE reallocation
addition
agriculture energy
balance
case
contribution
delay RVO
demand fat
detail
entity level
fuel segment
obligation
payment
production tax
protein
renewables market
sale material
segment sale
shift
turnaround DGD
volume ton
DAR Transcript
Darling Ingredients Inc. (DAR) Presents at 21st Annual Global Farm to Market Conference Transcript
Neutral5-13
Darling Ingredients Inc. (DAR) Q1 2026 Earnings Call Transcript
Positive4-30
The earnings call summary reveals strong financial performance, with revenue, net income, EBITDA, and operating cash flow all showing healthy year-over-year growth. Gross margin improvements and operational efficiencies are also positive indicators. Despite the lack of discussion on strategic initiatives or operational updates, the financial results alone suggest a positive sentiment. The absence of concerning insights from the Q&A section further supports a positive outlook for the stock price over the next two weeks.
Darling Ingredients Inc. (DAR) Q4 2025 Earnings Call Transcript
Positive2-12
The earnings call summary shows a positive outlook with strong demand for the collagen and gelatin business, promising developments in the Nextida product line, and expected higher margins from biofuels. The Q&A section supports this with strategic moves like the Brazil acquisition and a focus on core capabilities. Despite some management vagueness, the overall sentiment is positive with potential growth in EBITDA and international markets. These factors suggest a positive stock price movement.
Darling Ingredients Inc. (DAR) Q3 2025 Earnings Call Transcript
Unknown10-23
The earnings call presents a mixed outlook. While there are positive elements such as strong financial metrics, potential growth in the Feed Segment, and a promising joint venture, concerns arise from regulatory uncertainties, unclear guidance, and the hesitancy to provide precise forecasts. The Q&A section highlights these uncertainties, particularly around margins and regulatory impacts. The lack of clarity from management on critical issues tempers the positive aspects, leading to a neutral sentiment. Without a clear market cap, the stock price is expected to remain stable in the short term.
DAR Slides
DAR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
